Rahsaan Thompson - 24 Feb 2023 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Role
Chief Legal Officer
Signature
/s/ Hector Casab, as Attorney-in-Fact
Issuer symbol
LYEL
Transactions as of
24 Feb 2023
Net transactions value
$0
Form type
4
Filing time
28 Feb 2023, 17:15:29 UTC
Previous filing
12 Oct 2022
Next filing
25 Jun 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LYEL Option (right to buy) Award $0 +245,000 $0.000000 245,000 24 Feb 2023 Common Stock 245,000 $2.13 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 12.5% of the option shares shall vest on August 9, 2023, with the remaining option shares to vest in equal monthly installments over the following forty-two months.